Product Description |
Recombinant HEK293 cells stably express Angiotensin-converting enzyme 2 (ACE2) on the cell surface. The surface expression of ACE2 is validated by FACS analysis. This stable cell line product is designed for cell-based binding assays that measure the binding affinity and stability of antibody based biologics binding with ACE2, and can be utilized for SARS-Cov-2 pseudovirus neutralization assay for screening neutralizing antibodies. |
Applications |
Cell-based binding assay; neutralization assay; use as immunogen for antibody development. |
Expressed Gene |
NCBI reference sequence NM_021804.2; no expressed tags |
Target Protein |
NP_068576.1 |
Host Cell |
HEK293 |
Size |
Two vials of frozen cells (>1×106 per vial in 1 mL) |
Storage |
Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
Mycoplasma Status |
Negative. The mycoplasma test was performed with MycoAlert™ PLUS Mycoplasma Detection Kit (Cat. No. LT07-318, Lonza). |
Stability |
Stable through more than 20 passages with no significant changes in assay performance or expression profile. |
Culture Properties |
Adherent |
Freeze Medium |
95% complete growth medium, 5% DMSO (Cat. No. D2650, Sigma) |
Complete Growth Medium |
DMEM (Cat. No. 10569, Life Technologies), 10% FBS (Cat. No. 10099-141, Life Technologies) |
Culture Medium |
DMEM, 10% FBS, 250 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies) |
Gene Synonyms |
Angiotensin-converting enzyme 2, ACEH |
Background |
Angiotensin-converting enzyme 2 (ACE2), discovered as a homologue of ACE, acts as its physiological counterbalance providing homeostatic regulation of circulating angiotensin II (Ang II) levels. ACE2 is a zinc metalloenzyme and carboxypeptidase located as an ectoenzyme on the surface of endothelial and other cells. While its primary substrate appears to be Ang II, it can hydrolyze a number of other physiological substrates. Additionally, ACE2 functions in other noncatalytic cellular roles including the regulation of intestinal neutral amino acid transport. It also serendipitously acts as the receptor for the severe acute respiratory syndrome virus. Upregulation of ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders. ACE2 is regulated at multiple levels including transcriptional, posttranscriptional (miRNA and epigenetic), and posttranslational through its shedding from the cell surface. |

Figure 1: FACS analysis of cell surface expression of ACE2 on HEK293 cells.
HEK293/ACE2 cells (red) and negative control HEK293 cells (green) were stained with FITC conjugated SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479, GenScript).

Figure 5: FACS analysis of cell surface expression of ACE2 on HEK293 cells from different passages.
The HEK293/ACE2 cells and the negative control HEK293 cells were stained with FITC conjugated SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479, GenScript). P8, P13, P17 and P21 represent cell passage numbers.

Figure 4. SARS-CoV-2 (B.1.1.529) pseudovirus infection on HEK293/ACE2 cells. SARS-CoV-2 pseudovirus is prepared with S glycoprotein as the envelope protein. The pseudovirus entry was initiated by recognition and binding between S glycoprotein and ACE2 on HEK293 cells.

Figure 3. Neutralization assay of SARS-CoV-2 spike protein RBD by ACE2-Fc fusion proteins on HEK293/ACE2 cells. HEK293/ACE2 cells were incubated with 1 µg/ml SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479, GenScript) and ACE2-Fc fusion protein (Cat. No. Z03484, GenScript) in serial dilution. Then the cells were stained with THE™ His Tag Antibody [iFluor 488], (Cat. No. A01800, GenScript) and analyzed with flow cytometer.

Figure 2. Cell-based binding assay of SARS-CoV-2 spike protein RBD with HEK293/ACE2 cells. HEK293/ACE2 cells were incubated with SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479, GenScript) in serial dilution. Then the cells were stained with THE™ His Tag Antibody [iFluor 488] Mouse (Cat. No. A01800, GenScript) and analyzed with flow cytometer. FACS analysis shows the EC50 of spike protein RBD binding with ACE2 on HEK293 cells is 1.07 ug/ml.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
如您需要获取细胞系产品的说明书,请点击“Manual”,完善信息后点击“提交”。
我们会第一时间联系回复您。注意:中国地区购买的产品,说明书需要以中文站为准。
您也可拨打400-0258686转5810,或发邮件至product@genscript.com.cn联系我们。
更多产品文件类型 >>